Pharmaxis begins phase one clinical trial of compound targeting pancreatic cancer
The clinical trial will include two stages and outcomes will be released in June 2019.
Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 5 of 9
Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies
The results of the toxicity studies complete Pharmaxis’ scientific package of data for the LOXL2 program.
Pharmaxis resubmits new drug application for Bronchitol in the US
Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough. It is used for the treatment of cystic fibrosis patients.
Pharmaxis reveals first sales of Aridol® in US following successful relaunch
Aridol is a lung function test designed to help doctors diagnose and manage asthma.
Arix Bioscience sees multiple advancements across portfolio
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy
PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin
Pharmaxis moving into phase I clinical trial of its small molecule LOX inhibitor
Pharmaxis is the first company to progress a small molecule LOX inhibitor into clinical development.
Investments and investor services
BigDish beefs up on bid interest but is still below its flotation price
A look at day's gliders and sliders, including Integumen, MC Mining, Intermediate Capital, Bovis Homes and other house-builders, Dart Group,Flybe, easyJet, IAG, Learning Technologies and Oilex.
Archive
Proactive news snapshot: VR Education, Bigdish, Learning Technologies …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences hails phase I success of investee company Pharmaxis
Arix is a cornerstone investor in the ASX life sciences group
Investments and investor services
FTSE 100 closes marginally higher as PM May defends draft Brexit deal
The UK's premier share index closed up around four points at 7,038, while the FTSE 250 shed almost 248 points at 18,662.
Pharmaxis receives positive results from clinical trial of treatment for fibrotic diseases
There were no adverse safety findings and excellent drug-like properties were confirmed for the second of the LOXL2 inhibitor compounds.
Pharmaxis receives positive results from LOXL2 clinical trial
There were no adverse safety findings and excellent drug-like properties were confirmed.
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
Pharmaxis adds valuable experience with Ed Rayner appointment
Ed Rayner is an investment director for major shareholder Arix Bioscience Plc (LSE:ARIX).
Pharmaxis gains Arix Bioscience Plc as a new substantial shareholder
Arix led a $24 million share placement and will invest $14.2 million in two tranches.
Pharmaxis receives FDA approval to produce Aridol for US market
Aridol is already manufactured for the markets of Europe, Australia and South Korea.
Archive
Proactive news snapshot: Solo Oil, Metal Tiger, Tekcapital …
A glance at some of the day's highlights from the Proactive Investors newswire
IWG and Sabien Technology among Monday’s market losers
A look at some of the top risers and fallers in London today